News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Incyte Corporation Arthritis Drug Shows Promise; Positive Phase 2 Data Triggers $30 Million Milestone from Eli Lilly and Company
May 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Biotechnology firm Incyte Corp said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase 2
Eli Lilly and Company
Incyte
MORE ON THIS TOPIC
IPO tracker
Parabilis follows hefty Regeneron deal with IPO push
May 20, 2026
·
13 min read
·
Editorial Team
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
·
2 min read
·
Tristan Manalac
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
·
1 min read
·
Jef Akst
Rare diseases
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease
May 19, 2026
·
2 min read
·
Gabrielle Masson
